Dr. Fox is an Associate Professor of Medicine and a Clinician-Investigator in the Division of General Internal Medicine at Albert Einstein College of Medicine/Montefiore Medical Center. He graduated from the Albert Einstein College of Medicine in 2004, completed residency training at Montefiore in the Primary Care/Social Internal Medicine Residency Program in 2007, also serving as the PC/SM Chief Resident in 2008, and he received a Masters in Clinical Research from Einstein in 2012. Currently, he is a primary care physician at a Montefiore community health center in the South Bronx; the Co-Director of the Bronx Transitions Clinic, which links formerly incarcerated individuals with chronic health conditions to medical care; and conducts research focusing on opioid use disorder and the criminal justice system.
In 2012, Dr. Fox received a K23/career develop award from the National Institute on Drug Abuse to study "Buprenorphine Facilitated Access and Supportive Treatment (BUP-FAST) in Former Inmates". Since this time, he has received additional grant funding from NIDA, the New York State AIDS institute, the Society of General Internal Medicine, and has served as the site Principal Investigator for a Center for Medicare and Medicaid Innovations Award. These studies have focused on transitions of medical care from correctional facilities to the community, group-based buprenorphine treatment for opioid use disorder in primary care, and increasing treatment of Hepatitis C among formerly incarcerated individuals. Dr. Fox is board certified in Addiction Medicine and is a leader in integration of buprenorphine treatment for opioid use disorder into primary care and HIV settings.
Dr. Fox is also the course director for two medical student electives: "Research Based Health Activism" and “Health Disparities: From Awareness to Action”. He is a member of the National Physicians Alliance and has lectured extensively on physician advocacy.
1. Berland N, Fox AD, Tofighi B, Hanley K. Opioid Overdose Reversal Training with Naloxone, an Adjunct to Basic Cardiac Life Support Training for First Year Medical Students. Subst Abuse. IN PRESS
2. Riggins DP, Cunningham CO, Nin Y, Fox AD. Recent Incarceration is Not Associated with Poorer Buprenorphine Maintenance Treatment Outcomes Among HIV-positive Patients. Subst Abuse. IN PRESS
3. Hawks L, Norton BL, Cunningham CO, Fox AD. The Hepatitis C Virus cascade at an urban post-incarceration transitions clinic. J Viral Hepat. 2016 Jun; 23(6): 473-8.
4. Maradiaga JA, Nahvi S, Cunningham CO, Sanchez J, Fox AD. “I kicked the hard way. I got incarcerated.” Withdrawal from methadone during incarceration and subsequent aversion to medication assisted treatments. J Subst Abuse Treat. 2016 Mar; 62: 49-54.
5. Fox AD, Masyukova M, Cunningham CO. Optimizing psychosocial support during office-based buprenorphine treatment: patients’ experiences and preferences. Subst Abus. 2016 Jan-Mar; 37(1): 70-5.
6. Starrels JL, Peyser D, Haughton L, Fox AD, Merlin J, Arsten J, Cunningham CO. When HIV treatment goals conflict with guideline-based opioid prescribing: A qualitative study of HIV providers. Subst Abus. 2016 Jan-Mar; 37(1): 148-5.
7. Fox AD, Chamberlain A, Frost T, Cunningham CO. Harm reduction agencies as a potential site for buprenorphine treatment. Subst Abus. 2015 Apr-Jun; 36(2): 155-60.
8. Gonzalez CM, Fox AD, Marantz PR. The evolution of an elective in health disparities and advocacy: description of instructional strategies and program evaluation. Acad Med. 2015 Dec; 90(12): 1636-40.
9. Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of opioid dependent former inmates. Addict Sci Clin Pract. 2015 Jan 16; 10(1): 2.
10. Fox AD, Chamberlain A, Sohler NL, Frost T, Cunningham CO. Illicit buprenorphine use, interest in, and access to buprenorphine treatment among syringe exchange participants. J Subst Abuse Treat. 2015; 48(1): 112-6.
11. Fox AD, Anderson MR, Bartlett G, Valverde J, Starrels JL, Cunningham CO. Health outcomes and retention in care following release from prison for patients of an urban post-incarceration transitions clinic. J Health Care Poor Underserved. 2014; 25(3): 1139-52.
12. Fox AD, Anderson MR, Bartlett G, Valverde J, MacDonald RF, Shapiro LI, Cunningham CO. A description of an urban transitions clinic serving formerly incarcerated people. J Health Care Poor Underserved. 2014; 25(1): 376-82.
13. Fox AD, Shah PA, Sohler NL, Lopez CM, Starrels JL, Cunningham CO. I heard
about it from a friend: assessing interest in buprenorphine treatment. Subst Abus. 2014; 35(1); 74-9
14. Starrels JL, Wu B, Peyser D, Fox AD, Batchelder A, Barg FK, Arnsten JH, Cunningham CO. It made my life a little easier: Primary care providers’ beliefs and attitudes about using opioid treatment agreements. J Opioid Manag. 2014; 10(2): 95-102.
15. Shah PA, Sohler NL, Lopez C, Fox AD, Cunningham CO. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program. J Opioid Manag. 2013; 9(6): 407-13.
16. Cunningham CO, Giovanniello A, Kunins HV, Roose RJ, Fox AD, Sohler NL. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. Am J Addict. 2013; 22(4):352-7.
17. Fox AD, Sohler NL, Starrels JL, Ning Y, Giovanniello A, Cunningham CO. Pain is not associated with worse office-based buprenorphine treatment outcomes. Subst Abus. 2012; 33(4): 361-5.
18. Starrels JL, Fox AD, Kunins HV, Cunningham CO. They don’t know what they don’t know: internal medicine residents’ knowledge and confidence in urine drug testing interpretation for patients with chronic pain. J Gen Intern Med. 2012; 27(11): 1521-7.